Calidi Biotherapeutics reports Q1 GAAP EPS of -$0.43
Calidi Biotherapeutics reported a Q1 GAAP EPS of -$0.43.
The company’s cash position as of March 31, 2026, was $6.6 million, with an additional $0.2 million in restricted cash.
This compares to $5.6 million in cash and $0.2 million in restricted cash as of December 31, 2025.